Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)

ClinicalTrials.gov ID

NCT07101094

Lead Sponsor

Bristol-Myers SquibbINDUSTRY

Overall Status

Recruiting

Study Type

Observational

Enrollment

300Estimated

Last Update Posted

Aug 19, 2026Actual

Start Date

Sep 22, 2025Actual

Primary Completion Date

Jan 31, 2029Estimated

Completion Date

May 14, 2029Estimated

Official Title

Real-world Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)

Brief Summary

The purpose of this study is to understand treatment preference and satisfaction among adults with schizophrenia in the United States who are prescribed xanomeline and trospium chloride (X/T) therapy

• Schizophrenia

• xanomeline and trospium chloride (X/T) therapy

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

• Aged ≥18 years at index date.
• Have a confirmed diagnosis of schizophrenia before index date.
• Receipt of an initial prescription order for xanomeline and trospium chloride (XT) and plan to fill and initiate such therapy.
• Provide a signed and dated Institutional Review Board (IRB)/Independent Ethics Committee (IEC)-approved written informed consent form (ICF) in accordance with regulatory, local, and institutional guidelines.
• Agree to use an electronic device to record, or provide paper entry of, patient-reported outcomes (in English or Spanish).
• English or Spanish speaking.

Exclusion Criteria:

• Participation in an interventional study within the last 30 days or plan to participate in such study at the time of eligibility screening.
• Evidence of use of XT prior to time of eligibility screening.

Observational Model

Cohort

Time Perspective

Prospective

Lead Sponsor

Bristol-Myers SquibbINDUSTRY

312-399-3795

929-260-5003

317-560-2391

903-576-2629

• Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)

  NCT07379827

  RecruitingObservationalUpdated Aug 19, 2026
• Real-world Patient Characteristics, Treatment Patterns, and Healthcare Utilization Among KarXT Users

  NCT07571148

  Active, not recruitingObservationalUpdated May 6, 2026
• A Prospective, Observational, Single-Arm, Multicenter Real-World Study Evaluating the Treatment Pattern, Safety and Effectiveness of Xanomeline and Trospium Chloride Capsules (KarXT) in the Treatment of Chinese Adult Participants With Schizophrenia

  NCT07802132

  Not yet recruitingObservationalUpdated Sep 3, 2026
• An Open-Label Study to Evaluate the Efficacy and Tolerability of Xanomeline/Trospium In First Episode/Early Phase Schizophrenia Patients

  NCT06923891

  Not yet recruitingInterventionalPhase 4Updated Apr 11, 2025
• A Study to Assess Safety and Efficacy of KarXT in Adult Patients With Schizophrenia

  NCT03697252

  CompletedInterventionalPhase 2Updated Oct 26, 2020
• An Open-label Study to Assess the Long-term Safety, Tolerability, Effectiveness, and Durability of Effect of KarXT in Patients With DSM-5 Diagnosis of Schizophrenia

  NCT05643170

  TerminatedInterventionalPhase 3Updated Jun 12, 2024